Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY: LCTX )

0.4811 +0.0091 (+1.93%)
Streaming Delayed Price Updated: 3:14 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,068,796
Open 0.4688
Bid (Size) 0.4811 (1)
Ask (Size) 0.4833 (7)
Prev. Close 0.4720
Today's Range 0.4609 - 0.4989
52wk Range 0.3651 - 1.400
Shares Outstanding 174,986,671
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Which stocks are moving after the closing bell on Wednesday?
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill

Performance

YTD
-6.58%
-6.58%
1 Month
-10.29%
-10.29%
3 Month
-28.73%
-28.73%
6 Month
-44.72%
-44.72%
1 Year
-57.80%
-57.80%

More News

Read More
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics
Via Benzinga
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts
Via Benzinga
Lineage Cell Therapeutics's Earnings Outlook
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 10, 2025
Via Benzinga
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Issues Letter to Stockholders
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For November 14, 2024
Via Benzinga
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.